Hyphens Pharma gets exclusive rights to distribute European autoinjector

It will distributed in Singapore, Malaysia, the Philippines, and Vietnam.

Hyphens Pharma International Limited’s subsidiary, Hyphens Pharma, has obtained an exclusive right to market subcutaneous autoinjector Metoject pen.

Hyphens Pharma signed an agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to distribute in Singapore, Malaysia, the Philippines, and Vietnam for rheumatoid arthritis treatment.  

Metoject may also be used for the treatment of plaque psoriasis and has a lower intensity of certain gastrointestinal side effects compared to the oral drug.

The autoinjector pen’s design ensures simple two-step self-injection with an enhanced safety feature of a built-in needle and is available in multiple strengths including 7.5mg, 10mg, and 15mg.